Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
A 3-week, multi-center, open-label, randomized, active-control, parallel-group study to
compare effects of Nateglinide and Acarbose on postprandial glucose fluctuation in Chinese
drug-naive patients type 2 diabetes mellitus (T2DM). In this study, participants in different
groups took Nateglinide at a dose of 120 mg orally three times daily for up to 3 weeks or
Acarbose at a dose of 50 mg three times daily for up to 3 weeks, respectively.